Boehringer Ingelheim GmbH
Leoforos Andrea Syngrou 340, 176 73 Kallithea, Greece
Boehringer Ingelheim achieves next expansion milestone in biologics production in the US
- Culmination of a €200 million investment in California
- Worldwide capacity for manufacturing biopharmaceutical medicines now exceeds 290,000 liters
- Global manufacturing network for products in Boehringer Ingelheim’s own research pipeline and for contract manufacturing
Last week, employees joined with partners in politics and industry to celebrate the completed expansion of Boehringer Ingelheim’s biopharmaceutical manufacturing facility in Fremont, California. With a two-year investment totaling €200 million, the research-driven pharmaceutical company is creating 300 new jobs and increasing its worldwide bioreactor capacity to 290,000 liters. Boehringer Ingelheim is now well-positioned to manufacture future biopharmaceutical medicines, both from its own research pipeline and as a contract manufacturer for other pharmaceutical and biopharmaceutical companies.
“The completion of our expansion in Fremont marks another milestone in our biopharmaceutical growth strategy,” says Dr. Uwe Bücheler, Head of the Biopharmaceuticals Business Unit. “Our locations in the United States, Germany, Austria, and China are contributing to the development of innovative biopharmaceuticals for patients worldwide.”
In 1987 Boehringer Ingelheim brought Actilyse®, one of the first innovative biological medicinal products for the treatment of stroke and acute myocardial infarction, onto the market with a development partner. Today, biopharmaceuticals make up around 40 percent of the active ingredient candidates from the Boehringer Ingelheim research pipeline. Biotech contract manufacturing experienced double-digit growth in the past year and consolidated its global market leadership. Boehringer Ingelheim has an outstanding experience in manufacturing of 31 biopharmaceutical medicines for different customers worldwide.